Department of Reproductive Medicine

Steven Plaxe

Director, Division of Gynecologic Oncology Professor, Department of Reproductive Medicine University of California, San Diego UCSD Medical Center BUSINESS ADDRESS: Rebecca and John Moores UCSD Cancer Center 3855 Health Sciences Drive, Mail Code: 0987 La Jolla, CA 92093-0987 Academic Office: (858) 822-6199 Clinic Appointments: (858) 822-6100 Fax: (858) 822-6319 E-mail: splaxe@ucsd.edu

BOARD CERTIFICATION

• Obstetrics and Gynecology
• primary certification, 1989
• recertification, 1997
• Subspecialty Gynecologic Oncology
• primary certification, 1990
• recertification, 1997

EDUCATION

COLLEGE: Yale College
Degree: B.A. - Molecular Biophysics and Biochemistry
09/73 - 05/77

MEDICAL SCHOOL: Mount Sinai School of Medicine
Degree: M.D.
09/77 - 05/81

INTERNSHIP: Yale New Haven Hospital
07/81 - 6/82

RESIDENCY: Yale New Haven Hospital
07/82 - 06/85

FELLOWSHIP: Mount Sinai Hospital
Gynecologic Oncology
07/86 - 06/88

LICENSURE

• CA -
• NY - Inactive
• CT - Inactive

CURRENT RESEARCH

• Gynecologic Oncology Group - Principal Investigator at UCSD
• National Principal Investigator - GOG 192 - Randomized trial of Amifostine in patients with platinum induced neuropathy
• Epidemiology of gynecologic cancer

HONORS AND AWARDS

• Graduate Cum Laude: Yale College, 1977
• American Cancer Society Gerster Fellowship, 1979
• M. Ralph Kaufman Prize for Excellence in Psychiatry: Mt. Sinai School of Medicine, 1981
• Alpha Omega Alpha: Mt. Sinai School of Medicine, 1981
• Berlex Foundation Faculty Development Course, 1993
• Joseph M. Didio Teaching Award: UCSD Medical Center, 1994
• CREOG National Faculty Award for Excellence in Residency Education: UCSD Medical Center, 1994
• Ralphael Durfee Physician of the Year Award: Thrivers' Network, 1997
• Biotech All-Star: San Diego Padres Baseball Club, 2001
• San Diego Top Doctors, 2002, 2003, 2006
• Elected to Academy of Physician Scholars: University of California School of Medicine, 2004
• America's Top Obstetricians and Gynecologists: Consumers' Research Council of America, 2005, 2006
• Annual Faculty Award for Excellence in Clinical Care: University of California School of Medicine, 2005

PROFESSIONAL SERVICE

• Examiner: American Board of Obstetrics and Gynecology, Gynecologic Oncology
• Subspecialty Oral Exam, 2006, 2007
• Examiner: American Board of Obstetrics and Gynecology, General Oral Exam, 2001 - present
• Gynecologic Oncology Editorial Board, 2005 - present
• Society of Gynecologic Oncology Audit and Investment Committee, 2003 - present
• Society of Gynecologic Oncology Practice and Ethics Committee, 1999
• Vice President, Western Association of Gynecologic Oncologists, 1998
• Chair: Survivorship Subcommittee, Gynecologic Oncology Group Prevention and Control Committee, 2003 - present
• Gynecologic Oncology Group Prevention and Control Committee, Disparities Subcommittee, 2003 - present
• Gynecologic Oncology Group Ovarian Cancer Committee, 1999 - present
• Gynecologic Oncology Group Prevention and Control Committee, 1998 - present
• Gynecologic Oncology Group Development Therapeutics Committee, 1993 - 96
• Co-Editor: Up To Date, Endometrial Cancer Module
• Advisory Board, Granulosa Cell Tumor Foundation
• Manuscript Review
• American Journal of Obstetrics and Gynecology
• Gynecologic Oncology
• Obstetrics and Gynecology
• Annals of Oncology
• Journal of Clinical Oncology
• Cancer Research
• Clinical Cancer Research

ACADEMIC APPOINTMENTS

• Director, Division of Gynecologic Oncology University of California, San Diego
  07/95 - Present
• Professor, Reproductive Medicine University of California, San Diego
  1/01 - Present
• Associate Professor, Reproductive Medicine University of California, San Diego
  1/95 - 12/00
• Assistant Professor, Reproductive Medicine University of California, San Diego
  1/89 - 12/94
• Instructor in Obstetrics and Gynecology Mt. Sinai Medical Center
  07/88 - 12/88
• Clinical Assistant in Obstetrics and Gynecology Mt. Sinai Medical Center
  07/86 - 06/88
• Clinical Instructor in Obstetrics and Gynecology Yale University, School of Medicine
  07/85 - 06/86

HOSPITAL APPOINTMENTS

• UCSD Medical Center
• Hillcrest and Thornton Hospitals

Consulting Staff At:

• Mercy Hospital
• Grossmont Hospital
• Palomar Hospital
• Tri-City Hospital
• Sharp Memorial Hospital
• Palomar Pomerado Hospital
• Sharp Chula Vista Medical Center
• Scripps Chula Vista Medical Center
• Scripps Green Hospital
• Sharp Mary Birch Hospital
• Sharp Memorial Hospital
• Scripps Memorial Hospital
• Children's Hospital - San Diego, CA

PROFESSIONAL SOCIETY MEMBERSHIPS

• New Haven Obstetrical Society
• American Medical Association
• Society of Gynecologic Oncologists
• American Society of Clinical Oncology
• Western Association of Gynecologic Oncologists
• American College of Obstetrics and Gynecology, Fellow
• San Diego Medical Society
• San Diego Gynecologic Society
• American College of Surgeons, Fellow
• California Medical Society
• American Association for Cancer Research

BIBLIOGRAPHY

• Bruckner HW, Lavin P, Plaxe S, Storch JA and Livstone E: Absolute granulocyte, lymphocyte and monocyte counts as useful independent determinates of prognosis for patients with metastatic cancer of the stomach. JAMA 247(7):1004-06, 1982.
• Lavin PT, Bruckner HW, Plaxe S: Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 50:2016-2023, 1982.
• Bruckner H, Lavin P, Plaxe S, Storch JA and Livstone E: Routine clinical chemistries as improved determinates of prognosis for patients with metastatic cancer of the stomach. Oncology 40:31-35, 1983.
• Grannum P, Copel JA, Plaxe S, Scioscia AL, Hobbins JC: In utero exchange transfusion in severe erythroblastosis fetalis by direct intravascular injection. N Engl J Med 314:1434, 1986.
• Plaxe S and Decherney AH: When to suspect ectopic pregnancy. Diagnosis 8(3):137-140,1986.
• Deligdisch L, Plaxe S, Cohen CJ: Extrauterine pelvic malignant mixed mesodermal tumors - A study of ten cases with immunohistochemistry. Int J Gynecol Path 7:361-372, 1988.
• Plaxe SC, Dottino PR, Lipsztein R, Dalton J and Cohen CJ: Clinical features and treatment outcome of patients with epithelial carcinoma of the ovary metastatic to the central nervous system. Obstet Gynecol 75:278-281, 1990.
• Brodman M, Friedman F, Dottino P, Janus C, Plaxe S and Cohen C: A comparative study of computerized tomography, magnetic resonance imaging, and clinical staging for the detection of early cervix cancer. Gynecol Oncol 36:409-412, 1990.
• Plaxe SC, Dottino PR, Goodman HM, Deligdisch L, Idelson M and Cohen CJ: Clinical features of advanced ovarian mixed mesodermal tumor and treatment with doxorubicin- and cis-Platinum-based chemotherapy. Gynecol Oncol 37:244-249, 1990.
• Plaxe SC, Dottino PR and Cohen CJ: Therapeutic and Metabolic effects of high (>1 g/m2) systemic cumulative doses of cis-Platinum in patients with ovarian carcinoma. Gynecol Oncol 37:250-253, 1990.
• Plaxe SC, Deligdisch L, Dottino PR and Cohen CJ: Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol 38:367-372, 1990.
• Dottino PR, Plaxe SC, Beddoe AM, Johnston C, Cohen CJ: Induction chemotherapy followed by radical surgery in cervical cancer. Gynecol Oncol 40:7-11, 1991.
• Isonishi S, Kirmani S, Kim S, Plaxe SC, Braly PS, McClay EF and Howell SB: Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug resistance modulating agent dipyridamole. JNCI 83:621-626, 1991.
• Howell SB, Kirmani S, McClay EF, Kim S, Braly P and Plaxe S: Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Seminars Oncol 18:5-10, 1991.
• Dottino PR, Plaxe SC and Cohen CJ: A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer. Gynecol Oncol 43:198-203, 1991.
• Goel R, McClay EF, Kirmani S, Kim S, Braly PS, Plaxe SC, Alcaraz J., Andrews P.A., Reichman B., Markman M., Howell S.B. Pharmacokinetic study of intraperitoneal streptozotocin. Clin. and Invest. Med. 15:420-426, 1992.
• Christen RD, McClay EF, Plaxe SC, Yen SSC, Kim S, Kirmani S, Wilgus LL, Heath DD, Shalinsky DR, Freddo JL, Braly PS, O'Quigley J, Howell SB. In vivo modulation of cellular sensitivity to doxorubicin by high-dose progesterone. A phase I pharmaco-kinetic study. J. Clin. Oncol. 11:2417-2426, 1993.
• Plaxe SC, Braly PS, Freddo JL, McClay EF, Christen RD, Kirmani S, Kim S, Heath D, Howell SB. Phase I and pharmacokinetic study of intra-peritoneal ormaplatin. Gynecol. Oncol. 51:72-77, 1993.
• Plaxe SC, Braly PS and Dottino PR: A simplified approach to superficial inguinal dissection with sparing of the saphenous vein in patients with vulvar cancer. Surg Gynec Obstet 176:295-6,1993.
• Plaxe S, Dottino PR, Cohen CJ: Pelvic malignancy presenting as hernia in the female patient. Amer Family Physician 47:51-57, 1993.
• Kim S, Howell SB, McClay E, Kirmani S, Goel R, Plaxe S, Braly P, Bonetti A. Dose intensification of cisplatin chemotherapy through biweekly administration. Annals of Oncol 4:221-227, 1993.
• Plaxe SC, Braly PS, Freddo JL, McClay EF, Kirmani S, Howell SB. Profiles of young (age 30-39) and very young (age < 30) women with epithelial ovarian cancer. Obstet. and Gynecol. 81:651-654, 1993.
• Bonetti A, McClay E, Kirmani S, Goel R, Howell SB, Plaxe S, Braly P and Kim S: High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity. Gynecol Oncol 49:318-324, 1993.
• McClay EF, Goel R, Kirmani S, Kim S, Braly P, Plaxe S, McVey L, Hoff S and Howell SB: A phase I and pharmacokinetics study of intraperitoneal carboplatin and etoposide. Br J Cancer 68(4):783-788, 1993.
• McClay EF, Braly PS, Kirmani S, Plaxe SC, Kim S, McClay ME, Wilgus L, Howell SB. A Phase I trial of intraperitoneal carboplatin and etoposide with GM-CSF support in patients with intra-abdominal malignancies. Cancer 74:664-669, 1994.
• Plaxe S, Braly P, Freddo J, McClay E, Christen R, Kim S, Kirmani S, and Howell S: Phase I trial of cisplatin in combination with glutathione. J Gynecol. Oncol. 55:82-86, 1994.
• Kirmani S, Braly P, McClay E, Saltzstein S, Plaxe S, Kim S, Cates C, and Howell S: A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54:338-344, 1994.
• Plaxe S, Saltzstein S. Impact of ethnicity on the incidence of high-risk endometrial cancer. Gynecol Oncol 65:8-12, 1997.
• Fink D, Plaxe SC, Brown JF. Endometrioid ovarian carcinoma in a premenarchal girl: Report of a Case. Gynecol Oncol 67:222-225, 1997.
• Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen R, Lager DJ: Field cancerization: Why late recurrent ovarian cancer isn't recurrent. Am J Obstet Gynecol 178:641-649, 1998.
• Plaxe SC, Christen RD, O'Quigley J, Braly PS, Freddo JL, McClay E, Heath D, Howell SB. Phase I and pharmacokinetic study of intraperitoneal topotecan. Investigational New Drugs 16:147-153, 1998.
• Aebi S, Schnider TW, Los G, Heath DD, Darrah D, Kirmani S, McClay EF, D'Agostino H, Plaxe SC, Fink D, De las Alas MM, Howell SB, Christen RD: A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol 44:259-265, 1999.
• Gooding JM, D'Agostino HB, Plaxe SC: Transcervical metallic stents for drainage of uterine collections. J Vasc Interv Radiol 10(5):629-33, 1999.
• Plaxe SC, Saltzstein SL: Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 75:55-61, 1999.
• De las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S, D'Agostino HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los G: Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemother Pharmacol 45:381-388, 2000.
• Plaxe, SC, Blessing JA, Lucci JA, Hurteau JA: A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix. Invest New Drugs 19: 77-80, 2001.
• Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ: Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 84:241-244, 2002.
• Plaxe SC, Blessing JA, Bookman MA, Creasman WT: Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 84:32-35, 2002.
• Plaxe SC, Blessing JA, Morgan MA, Carlson J: Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. Feb;25(1):45-7, 2002.
• Plaxe SC, Blessing JA, Olt G. Husseinzadah N, Lentz SS, DeGeest K, Valea FA: A phase II of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Chemother Pharmacol. Aug;50(2):151-4, 2002

INVITED EDITORIALS

• Plaxe SC: Chasing zebras: The study and treatment of rare diseases. Gynecol Oncol. Feb; 100(2): 227-8, 2006.

BOOK CHAPTERS

• Buchsbaum H and Plaxe SC: The urinary tract and radical hysterectomy in Gynecologic and Obstetric Urology, Third Edition. W.B. Saunders Company, Philadelphia, PA, pp. 171-188, 1993.
• Buchsbaum H and Plaxe SC: Clinical and operative obstetrics in Gynecologic and Obstetric Urology. W.B. Saunders Company, Philadelphia, PA, pp. 621-630, 1993.
• Plaxe SC. Editor: Gynecologic Oncology in Current Opinions in Obstetrics and Gynecology. Current Science, Philadelphia, PA, 6:65-66, 1994.

ABSTRACTS

• Bruckner HW, Lavin P, Plaxe S, Storch JA and Livstone E. Objective laboratory tests as prognostic determinates for the analysis of gastric cancer trials. Gastrointestinal Tumor Study Group. Proceedings AACR 21:180, 720, 1980.
• Grannum P, Copel JA, Scioscia A, Plaxe S, Hobbins JC: Intravascular intrauterine exchange transfusion. Presented at the Sixth Annual Meeting, Society of Perinatal Obstetricians. January 30-February 01, 1986.
• Plaxe S, Dottino PR, Goodman HM, Deligdisch L, Idelson M, Cohen CJ: Treatment of advanced ovarian mixed mesodermal tumors with Doxorubicin and Cisplatinum based chemotherapy. Gynecol Oncol 32:130, 1989.
• Plaxe S, Dottino PR and Cohen CJ: Clinical features and implications of atypical metastatic disease spread of epithelial ovarian carcinoma. Gynecol Oncol 32:129, 1989.
• Plaxe SC, Dottino PR and Cohen CJ: Metabolic effects of high (>1 gm/M2) systemic cumulative doses of cisplatinum. Gynecol Oncol 32:129, 1989.
• Brodman M, Friedman R, Dottino P, Janus C, Plaxe S and Cohen C: Comparison of clinical staging computerized tomography and magnetic resonance imaging in the staging of cervix cancer. Gynecol Oncol 32:130, 1989.
• Dottino P, Plaxe S and Cohen C: Cisplatinum and doxorubicin chemotherapy in the treatment of stage I ovarian cancer. Gynecol Oncol 32:129, 1989.
• Dottino P, Plaxe S and Cohen C: Neoadjuvant chemotherapy followed by radical surgery in cervical cancer. Gynecol Oncol 32:129, 1989.
• Dottino P, Plaxe S and Cohen C: Combination chemotherapy and radiotherapy in the treatment of cervical cancer. Gynecol Oncol 32:129, 1989.
• Plaxe SC, Dottino PR and Cohen CJ: Patients with separate primary carcinomas of breast and ovary: Treatment considerations and clinical features. Pro Int Gynecol Cancer Soc, Toronto, Canada, 1989
• Plaxe SC, Deligdisch L, Dottino PR, Cohen CJ: Ovarian intraperitoneal neoplasia (OIN) demonstrated in patients with stage I ovarian carcinoma. Society of Gynecologic Oncologists, February 1990 - Presented.
• Kim S, McClay E, Kirmani S, Goel R, McVey L, Plaxe S, Braly P, Howell S: Biweekly intravenous (IV) Cisplatin with sodium thiosulfate (STS). Proceedings - American Society of Clinical Oncology 9:86, 1990.
• McClay EF, Goel R, Kirmani S, McVey L, Kim S, Braly P, Plaxe SC, Alcaraz J, Hoff S and Howell SB: A phase I (PHI) pharmacokinetic study of carboplatin (CBDCA) and etoposide (VP-16) administered via the intraperitoneal (IP) route. Proceedings - American Society of Clinical Oncology 9:85, 1990.
• McClay EF, Kirmani S, Kim S, Braly P, Plaxe S, McClay ME, Wilgus L, Hoff S and Howell SB: Phase I trial of high dose carboplatin (CBDCA) and VP-16 via the intra peritoneal (IP) route with human recombinant granulocytemacrophage-colony stimulating factor (GM-CSF) support. Proceedings - American Society of Clinical Oncology 10:96, 1991.
• Goel R, McClay EF, Kirmani S, Kim S, Braly PS, Plaxe SC, Alcaraz J, Andrews PA, Reichman B, Markman M, Howell SB. Pharmacokinetic study of intraperitoneal streptozotocin. Proc. Am. Assoc. Cancer Research. 32:173, 1991.
• Plaxe S, Braly P, McClay E, Kirmani S, Kim S and Howell S: Prognosis of very young patients (<30 years of age) with epithelial ovarian cancer. Proceedings - American Society of Clinical Oncology 11:227-(721), 1992.
• Plaxe S, Braly P, McClay E, Kirmani S, Kim S and Howell S: Outcome of five year survivors with ovarian carcinoma (OC). Proceedings - American Society of Clinical Oncology 11:237(761), 1992. Presented at Western Association of Gynecologic Oncologists - Durango, CO June 1992.
• Kirmani S, McClay EF, Kim S, Braly P, Plaxe S and Howell SB: A Phase I trial of concurrent intraperitoneal (IP) cisplatin (CDDP) and carboplatin (CBDCA). Proceedings - American Society of Clinical Oncology 11:129(336), 1992.
• Christen RD, McClay EF, Plaxe SC, Freddo JL, Braly PS, Kim S, Kirmani S, Qvistgaard D, Heath DD, Shalinsky DR, Howell SB. In vivo modulation of doxorubicin by progestation agents. Proc. Amer. Soc. Clin. Oncol. 12:148(392), 1993.
• Kirmani S, Braly PS, McClay EF, Saltzstein SL, Plaxe SC, Kim S, Cates C, Howell SB. A phase III trial comparing intraperitoneal (ip) versus intravenous (iv) chemotherapy for ovarian cancer. Proc. Am. Soc. Clin. Oncol. 12:270(865), 1993.
• Plaxe, SC, Braly P, Freddo J, McClay E, Kiramani S, Kim S, Howell S. Phase I study of intraperitoneal ormaplatin demonstrates feasibility and pharmacologic advantage. Society of Gynecologic Oncologists, Palm Desert 34:402(2399) 1993.
• Plaxe S, Christen R, O'Quigley J, Braly P, Freddo J, McClay E, Heath D, Howell S. Phase I trial of intraperitoneal topotecan. ASCO 12:140(360), Orlando 1993.
• Plaxe S, Braly P, Freddo J, McClay E, Kirmani S, Kim S, Christen R, Heath D, Howell S. Phase I trial of intraperitoneal (ip) ormaplatin (op) with extended pharmacokinetic (pk) assessment. AACR, 34:402(2399), Orlando 1993.
• Ibrahim M, Plaxe S, Freddo J, Braly P. Critical analysis of mortality on a uni-versity gynecologic oncology service. ASCO, 1993, Orlando 12:440(1520) Presented.
• Plaxe S, Freddo J, Kim S, Kirmani S, McClay E, Christen R, Braly P, and Howell S. Phase I trial of cisplatin (DDP) and glutathione (GSH). Soc Gynecol Oncology, Orlando, FL, 52:109 (28),1994.
• Plaxe S, Saltzstein S. Demographic characteristics (DC) identify populations at risk for poor prognostic factors (PF) in primary gynecologic malignancy (GM). An analysis of 30,601 newly diagnosed patients presenting in California from 1988-91. Soc Gynecol Oncology, San Francisco, 78(22), 1995.
• D'Agostino H, Plaxe S, Beale A, Sewall B, Stapakis J, Fischbach T, Kinney T, Rose S. Transvaginal metallic stent placement for drainage of hematometra and pyometra. Soc Minimally Invasive Therapy, 1995, Oregon 4:(0-137).
• Gurin C, Plaxe S. Impact of age and year of diagnosis on stage in cervical cancer (CxCa). Western Association of Gynecologic Oncologists, 1995, Coeur d'Alene, Idaho. (Presented)
• Skilling JS, Knowlton S, Sood A, Baergen R, Plaxe S, Buller RE. Late Recurrent Ovarian Carcinoma: Tumor Dormancy or New Cancer?. Soc Gynecol Oncology, New Orleans, LA, 60:(1) (13), 1996.
• Plaxe S, Saltzstein S. Incidence of high risk histology in endometrial carcinoma (EC) is similar in black (B) and white (W) women. Soc Gynecol Oncology, New Orleans, LA, 60:(1) (14), 1996.
• Aebi S, Los G, Kirmani S, McClay EF, D'Agostino H, Plaxe S, Darrah D, Heath DD, Howell SB, Christen RD. High dose progesterone (P) enhances the therapeutic effect of paclitaxel (TAX). ASCO, 15: (1557), 1996.
• Alas de las M, Christen RD, Kirmani S, D'Agostino HR, Plaxe S, Darrah D, McClay EF, Howell SB, Los G. Correlation between tumor response and change in GADD153 mRNA level in human biopsies after paclitaxel treatment. ASCO, 15: (571), 1996.
• Scioscia A, Budorick N, Reisner L, Roberts A, Mattrey R, Baergen R, Plaxe S. Multidisciplinary protocol for management of patients with prenatal diagnosis of placenta percreta. Soc Perinatal Obst, 176: (1):S143 (494), 1997.
• Plaxe S, Saltzstein S. Successful early detection and preventive treatment of cervical neoplasia (CN) decreases with age. Soc Gynecol Oncology, 1997, Phoenix, AZ. (Accepted)
• D'Agostino HB, Plaxe SC, Rose SC, Gimenez M, Anchorena F, Serra, E. Percutaneous lieostomy for decompression of malignant small bowel obstruction. Supplement to Radiology, 209: 402 #1191, 1998.
• D'Agostono HB, Plaxe SC, Rose SC, Gimenez M, Anchorena F, Serra E. Percutaneous lieostomy for decompression of malignant small bowel obstruction. Supplement to Radiology, 209, 402#1191, 1998.
• Plaxe SC, Saltzstein SL. Prevention of cervical adenocarcinoma through screening is feasible. Soc Gynecol Oncol, 72:460 (65), 1999.
• Plaxe SC. Higher node counts are not associated with better survival in node negative endometrial cancer patients. Society of Gynecologic Oncologists, 2004.
• Plaxe SC Staging in ovarian cancer. Society of Gynecologic Oncologists, 2003.
• Plaxe, SC and Salzstein SL. Black women have a lower incidence of cervical carcinoma-in-situ but a higher incidence of invasive cervical cancer than do white women. Society of Gynecologic Oncologists, 2001

INVITED LECTURESHIPS AND PRESENTATIONS

• "Clinical Features and Treatment of Mixed Mesodermal Tumors of the Ovary." Grand Rounds - Department of Obstetrics and Gynecology, St. Louis University, St. Louis, MO. August 1986.
• "Mixed Mesodermal Tumors of the Ovary - Treatment and Immunohistochemical Staining." Grand Rounds - Department of Obstetrics and Gynecology, Stanford University, Stanford, CA. January 1987.
• "Mixed Mesodermal Tumors of the Ovary." Grand Rounds - Department of Obstetrics and Gynecology, University of Florida, Gainesville, FL. February 1989.
• "Speaker, "Vulvar and Endometrial Carcinoma." Osler Institute Review Course, Los Angeles, CA. July 1989.
• "Pre- and Postoperative Care of the Elderly Woman." San Diego Gynecologic Society Symposium, San Diego, CA. January 20, 1990.
• Grand Rounds, "New Approaches to Cervical Cancer Treatment." Balboa Naval Hospital, San Diego, CA. March 20, 1990.
• Invited Speaker, "Clinical Gynecologic Oncology." Oncology Nursing Course, Mercy Hospital, San Diego, CA. February 22, 1991.
• Grand Rounds, "Carcinoma of the Vulva - Changing Concepts and Unusual Tumors." Balboa Naval Hospital, San Diego, CA. March 19, 1991.
• Invited Speaker, "Gynecologic Cancer" - Radiology for the Non-Radiologist (continuing education course), Coronado, CA. August 15, 1991.
• Invited Speaker, "Phase I and Pharmacokinetic Trial of Intraperitoneal Ormaplatin National Cancer Institute Phase I Trails working meeting." Bethesda, MD. March 10, 1992.
• Invited Speaker, "High Dose Cisplatin", Venice, Italy. April 5, 1992.
• Invited Speaker, "Phase I and Pharmacokinetic Trial of Intraperitoneal Ormaplatin, National Cancer Institute Phase I Trials working meeting." Bethesda, MD. October 28, 1992.
• Invited Speaker, "Ovarian Cancer", Planned Parenthood of San Diego & Riverside Counties, San Diego, CA 1993.
• Invited Speaker, "Ovarian Cancer", American Council of Life Insurance, San Diego, CA. June 12, 1994.
• Invited Speaker, "Endometrial Carcinoma", San Diego County Cancer Registrars Association, San Diego, CA. November 10, 1995.
• Invited Speaker, "Ovarian Cancer", Alvarado Tumor Board, San Diego, CA. 1996.
• Invited Speaker, "Ovarian Cancer", Grand Rounds, UCSD Medical Center, San Diego, CA. July 3, 1996.
• Invited Speaker, "Endometrial Cancer", Alvarado Tumor Board, San Diego, CA. June 5, 1997.
• Invited Speaker, "Cervical Cancer in Pregnancy", Alvarado Department of Ob/Gyn Program, San Diego, CA. May 5, 1998.
• Invited Speaker, "Ovarian Carcinoma Update", Sharp Hospital Tumor Board, Chula Vista, CA. May 6, 1998
• Invited Speaker, "Ovarian Carcinoma Update", Tri-City Hospital Tumor Board, Oceanside, CA. June 5, 1998;
• Invited Speaker, "Ovarian Carcinoma Update", Gyn Cancer Conference Tumor Board, Palomar Hospital, San Diego, CA. August 4, 1998.
• Invited Speaker, 'New Developments in the Treatment of Recurring Ovarian Cancer, Cedars-Sinai Hospital, Los Angeles, CA. January 29, 1999.
• Invited Speaker, A Gynecologic Oncology Update Seminar: "Current GOG Protocols", University of California, San Diego, CA. January 30, 1999.
• Invited Speaker, Clinical Trials Meeting: "Gynecologic Oncology Group Clinical Trials", La Jolla, CA. March 11, 1999.
• Invited Speaker, "New Developments in the Treatment of Recurring Ovarian Cancer", SmithKline Beecham Pharmaceuticals Oncology Division, Portland, OR. April 25, 1999.
• Invited Speaker, Berkeley Tumor Board, Oakland, CA. May 6, 1999.
• Invited Speaker, "New Developments in the Treatment of Recurring Ovarian Cancer", SmithKline Beecham Pharmaceuticals Oncology Division, AZ. June 18, 1999.
• Invited Speaker, "New Developments in the Treatment of Ovarian Cancer", Palomar Tumor Board, Escondido, CA. May 5, 2000.
• Invited Speaker, "Optimal vs Suboptimal Tumor Debulking" Scripps Green Tumor Board, La Jolla, CA. May 9, 2000.
• Invited Speaker, "Small Cancer of the cervix - Surgery should the primary treatment." Gynecologic Oncology Group Semi-Annual Meeting. Summer, 1999
• Moderator. Lunchtime debate, "Surgical Staging in Endometrial Cancer." Discussant Robinson, et al "Osteoporosis in Cancer Patients on Chemotherapy", Society of Gynecologic Oncology Annual Meeting. Miami, FL: Summer, 2005.

INSTITUTIONAL SERVICE

• Credentials Committee, UCSD Medical Center, 1990-1996
• Ad-Hoc Committee on Resident Training, Department of Reproductive Medicine, UCSD Medical Center, 1990
• Residency Selection Committee, Department of Reproductive Medicine, UCSD Medical Center, 1990-91
• UCSD Operating Room Products Committee, 1991-1992
• Committee on Investigation of Human Subjects, UCSD Medical Center, 1991-1996
• Operative Services Task Force Committee, UCSD Medical Center, 1993-1996
• Academic Review Committee, UCSD Medical Center, 2000-2001
• UCSD School of Medicine Committee on Appointments and Promotions, 1998-99, 2003-4, 2004-5 (Chair)
• UCSD School of Medicine Health Sciences Faculty Council, 2004-05
• UCSD Department of Reproductive of Medicine Clinical Compensation Committee, 2003
• UCSD Department of Reproductive Medicine Executive Council, 2000 - present.
• UCSD Rebecca and John Moores Comprehensive Cancer Center Executive Committee, 2004 - present
• USCD Rebecca and John Moores Comprehensive Cancer Center: Specialized Cancer Unit Leader for Gynecologic Oncology, 2000 - present
• Academy of Clinician Scholars Committee on Clinical Excellence, 2005 - present
• Block Time Subcommittee for UCSD Operating Rooms, 2005 - present
• Rebecca & John Moores UCSD Cancer Center Compensation Plan Committee, 2005 - present

TEACHING

• Mitch Kamrave - ISP chair
• Vickie NG - ISP chair
• 403b - Fourth year elective in Gynecologic Oncology
• 401 - Third year medical students
• Lecture - Surgical Anatomy of the Pelvis - Second year medical students